- Acute pain management
- Amyotrophic Lateral Sclerosis (ALS)
- Chronic pain
- Huntington’s Disease
- Inflammatory bowel disease
- Parkinson’s Disease
- Post-Traumatic Stress Disorder
- Multiple Sclerosis
- Opioid substitution
- Spinal cord damage
- **Any other condition that the practitioner believes can be treated with medical cannabis (as of January 2022)
PATIENT POSSESSION LIMITS
As initially implemented, the law permits qualified patients to possess a 30 day supply of cannabis-infused, non-smokable products. but only non-smokable preparations allowed. Regulations announced by the Department of Health in 2017 state, “[R]egistered organizations will be allowed to manufacture and distribute additional products including topicals such as lotions, ointments and patches, as well as solid and semi-solid products including chewable and effervescent tablets and lozenges. Certain non-smokable forms of ground plant material will also be permissible for manufacture and distribution.” Legislation signed into law in 2021 amended these rules to permit qualified patients to possess a 60-day supply of cannabis and removed the prior prohibitions on smoking.
Yes. Members of of the New York Cannabis Control Board advanced regulations on October 21, 2021 permitting qualified patients to home-cultivate up to six plants per private residence. The regulations will take effect following a 60-day public comment period and finalization from the Board.
Yes, as initially enacted, five producers of cannabis-based preparations and up to 20 dispensing centers were to be licensed by the state. In 2017, the Department of Health registered five additional entities to manufacture and dispense cannabis-infused products.
STATE-LICENSED DISPENSARIES OPERATIONAL
Yes, each certified patient may have up to two caregivers, and each caregiver may serve no more than five certified patients.
ESTIMATED NUMBER OF REGISTERED PATIENTS
- Source: New York State Department of Health, as of December 28, 2021